Palvella Therapeutics (PVLA) Q3 2025 Financial Results Summary

Palvella Therapeutics (PVLA) Q3 2025 Financial Results Summary

Palvella Therapeutics, Inc. (Nasdaq: PVLA) released its financial results for the third quarter ending September 30, 2025, on November 11, 2025. Below is a summary of the key highlights and financial metrics from the report.

Financial Highlights:

• Cash Position:
• Cash and cash equivalents amounted to $63.6 million as of September 30, 2025.

• This amount is projected to fund operations into the second half of 2027.

• Research and Development Expenses:

• For Q3 2025, R&D expenses totaled $6.5 million, an increase of 103.7% from $3.2 million in Q3 2024.

• The rise is attributed to enhanced spending on the clinical development of QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations and cutaneous venous malformations.

• General and Administrative Expenses:

• General and administrative expenses reached $3.6 million in Q3 2025, compared to $1.9 million in Q3 2024, reflecting a 89.5% year-over-year increase.

• Net Loss:

• The net loss attributable to common stockholders was $11.3 million, or $1.03 per basic and diluted share, for Q3 2025.

• This marks a significant increase from a net loss of $7.0 million or $3.94 per share reported in Q3 2024, representing a 61.4% year-over-year increase.

• Shares Outstanding:

• As of November 7, 2025, total shares outstanding were 13,768,036, which includes 11,836,490 shares of common stock and 1,931,546 common share equivalents.

Corporate Developments:

• Clinical Trials:
• The Phase 2 TOIVA trial for QTORIN™ rapamycin concerning cutaneous venous malformations is expected to release top-line results in mid-December 2025.

• The Phase 3 SELVA trial for microcystic lymphatic malformations is on track to provide results in the first quarter of 2026.

• New Product Developments:

• Initiation of a Phase 2 study for treating clinically significant angiokeratomas is anticipated in the second half of 2026.

• Introduction of a new QTORIN™ product candidate, QTORIN™ pitavastatin, for disseminated superficial actinic porokeratosis, with Phase 2 study initiation also expected in the second half of 2026.

• Management Update:

• David W. Osborne, Ph.D., was appointed as Chief Innovation Officer to lead early-stage R&D, enhancing the potential of Palvella’s QTORIN™ platform.

Research and Development Highlights:

• FDA Engagement:

• The FDA awarded proceeds from the Orphan Products Grant to support ongoing clinical trials, emphasizing the progress and recognition of Palvella’s programs.

• Research Publications:

• A publication highlighted the potential of off-label rapamycin use for treating venous malformations and reinforced the need for a targeted topical treatment, which Palvella aims to address with QTORIN™ rapamycin.

Dividend and Share Repurchase Information:

• Quarterly Dividend:

• There is no mention of a declared quarterly dividend for Q3 2025 in the report.

• Share Repurchase:

• No share repurchase programs were indicated in the financial report.

Conclusion

Palvella Therapeutics continues to advance its rare disease pipeline, focusing on innovative treatments for serious skin conditions. With significant increases in R&D and administrative expenses, the company is investing heavily in its future product candidates. The financial results reflect continued operational losses as the firm builds toward potential regulatory approvals for its lead product candidates. All eyes will be on the upcoming trial results as Palvella seeks to solidify its position in the biopharmaceutical market.

For more information, please visit Palvella Therapeutics.

Here are the extracted tables from the press release:

PALVELLA THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share amounts)

---

PALVELLA THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEET INFORMATION (in thousands)